BioSpace News Archive

Iridex Corporation reported financial results for the fourth quarter and year ended January 1, 2022.

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing novel T cell engagers, reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.

Lucira Health, Inc., a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, reported financial results for the fourth quarter and full year ended December 31, 2021.

Gritstone bio, Inc., a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, reported financial results for the fourth quarter and full year ended December 31, 2021 and provided recent clinical and corporate updates.

Amgen will virtually present at the 32nd Annual Oppenheimer Healthcare Conference at 11:20 a.m. ET on Wednesday, March 16, 2022.

Movano Inc., a health technology company designing devices that inspire and empower you to live a healthier, happier life, announced that it will report fourth quarter 2021 financial and operating results on Thursday, March 24, 2022.

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, today reported financial results for fourth quarter and full year 2021 and provided a business update.

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, reported its fourth quarter and full year 2021 financial results.

Lantern Pharma Inc. announced financial results and operational highlights for the fourth quarter and fiscal year ended December 31, 2021.

Myeloid Therapeutics, Inc., a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases, announced that company management will present a corporate overview at Oppenheimer’s 32nd Annual Healthcare Conference and will participate in one-on-one meetings with investors.